Neoadjuvant Study of Targeting ROS1 in Combination With Endocrine Therapy in Invasive Lobular Carcinoma of the Breast (ROSALINE)

NCT04551495 · clinicaltrials.gov ↗

PHASE2

Phase

UNKNOWN

Status

65

Enrollment

OTHER

Sponsor class

Conditions

Invasive Lobular Breast Carcinoma
ER+ Breast Cancer
HER2-negative Breast Cancer

Interventions

DRUG: Entrectinib
DRUG: Letrozole
DRUG: Goserelin

Sponsor

Jules Bordet Institute

Collaborators

[object Object]